Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.39 |
| ▸ | KLK7 | P49862 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744418 | 1.00 | PDE4B (0.52) | PDE4BF13A1TGM2TGM1BACE1 | |
| SCHEMBL18264070 | 0.93 | PDE4B (0.44) | PDE4BBACE1BACE2L3MBTL1KMT2A | |
| SCHEMBL18270857 | 0.93 | PDE4B (0.44) | PDE4BBACE1BACE2L3MBTL1KMT2A | |
| SCHEMBL1360264 | 0.90 | PDE4B (0.56) | PDE4BBACE1BACE2L3MBTL1KMT2A | |
| SCHEMBL1360262 | 0.90 | PDE4B (0.56) | PDE4BBACE1BACE2L3MBTL1KMT2A | |
| SCHEMBL7496914 | 0.87 | PDE4B (0.55) | PDE4BBACE1BACE2L3MBTL1KMT2A | |
| SCHEMBL2183565 | 0.86 | PDE4B (0.55) | PDE4BF13A1TGM2TGM1L3MBTL1 | |
| SCHEMBL12426648 | 0.86 | PDE4B (0.55) | PDE4BF13A1TGM2TGM1L3MBTL1 | |
| SCHEMBL2180969 | 0.86 | PDE4B (0.55) | PDE4BF13A1TGM2TGM1L3MBTL1 | |
| SCHEMBL30060223 | 0.86 | PDE4B (0.59) | PDE4BBACE1BACE2L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729063-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-8362003-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | PDE4B 1536/4885F13A1 691/4885TGM2 4276/4885 |
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR3 | PDE4B 2341/4885F13A1 557/4885TGM2 4201/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | PDE4B 2341/4885F13A1 557/4885TGM2 4201/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | PDE4B 1536/4885F13A1 691/4885TGM2 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.